Skip to content Skip to footer

About mbiomics


mbiomics offers a unique combination of fast, quantitative and accurate analysis of the microbiome.

mbiomics is a pioneer in targeted microbiome profiling. Our patented precision technology enables unparalleled quantitative resolution and drastically faster microbiome analysis. This creates a basis for various future clinical applications and it will accelerate microbiome-based therapeutics development.

Our partners

We work with industry leaders across the medical, technology and biotechnology industries, as well as renowned academic institutions, on both clinical research and commercial product development.

University of Zurich


Dr. Laura Figulla

CEO | Co-Founder

Dr. Markus Rinecker

CMO/CFO | Co-Founder

Dr. Johannes B. Woehrstein

CTO | Co-Founder

Dr. Heinrich Grabmayr


Get in touch with mbiomics